124 related articles for article (PubMed ID: 12076452)
21. A multicenter, randomized, phase III study of docetaxel plus best supportive care versus best supportive care in chemotherapy-naive patients with metastatic or non-resectable localized non-small cell lung cancer (NSCLC).
Roszkowski K; Pluzanska A; Krzakowski M; Smith AP; Saigi E; Aasebo U; Parisi A; Pham Tran N; Olivares R; Berille J
Lung Cancer; 2000 Mar; 27(3):145-57. PubMed ID: 10699688
[TBL] [Abstract][Full Text] [Related]
22. A rapid and systematic review of the clinical effectiveness and cost-effectiveness of topotecan for ovarian cancer.
Forbes C; Shirran L; Bagnall AM; Duffy S; ter Riet G
Health Technol Assess; 2001; 5(28):1-110. PubMed ID: 11701100
[TBL] [Abstract][Full Text] [Related]
23. Randomized trial of paclitaxel plus supportive care versus supportive care for patients with advanced non-small-cell lung cancer.
Ranson M; Davidson N; Nicolson M; Falk S; Carmichael J; Lopez P; Anderson H; Gustafson N; Jeynes A; Gallant G; Washington T; Thatcher N
J Natl Cancer Inst; 2000 Jul; 92(13):1074-80. PubMed ID: 10880550
[TBL] [Abstract][Full Text] [Related]
24. Docetaxel in the treatment of non-small cell lung cancer: review of single-agent trials.
Fossella FV
Semin Oncol; 1999 Oct; 26(5 Suppl 16):17-23; discussion 41-2. PubMed ID: 10585004
[TBL] [Abstract][Full Text] [Related]
25. New options in the treatment of non-small cell lung cancer.
Fossella F; Rigas JR; Belani CP
Anticancer Drugs; 1999 Nov; 10 Suppl 1():S25-8. PubMed ID: 10630365
[TBL] [Abstract][Full Text] [Related]
26. Single agents in the second-line treatment of non-small cell lung cancer.
Belani CP
Semin Oncol; 1998 Jun; 25(3 Suppl 8):10-4. PubMed ID: 9704670
[TBL] [Abstract][Full Text] [Related]
27. The current status of docetaxel for advanced non-small cell lung cancer.
Green MR
Anticancer Drugs; 2001 Feb; 12 Suppl 1():S11-6. PubMed ID: 11340898
[TBL] [Abstract][Full Text] [Related]
28. The role of docetaxel (Taxotere) as a single agent or in combination before local treatment of non-small cell lung cancer.
Harper P
Semin Oncol; 1997 Aug; 24(4 Suppl 14):S14-30-S14-32. PubMed ID: 9335522
[TBL] [Abstract][Full Text] [Related]
29. A systematic overview of chemotherapy effects in non-small cell lung cancer.
Sörenson S; Glimelius B; Nygren P;
Acta Oncol; 2001; 40(2-3):327-39. PubMed ID: 11441939
[TBL] [Abstract][Full Text] [Related]
30. A comparison of the costs of paclitaxel and best supportive care in stage IV non-small-cell lung cancer.
Earle CC; Evans WK
Cancer Prev Control; 1997 Oct; 1(4):282-8. PubMed ID: 9765752
[TBL] [Abstract][Full Text] [Related]
31. Docetaxel (taxotere) in the treatment of non-small cell lung cancer.
Georgoulias V
Curr Med Chem; 2002 Apr; 9(8):869-77. PubMed ID: 11966449
[TBL] [Abstract][Full Text] [Related]
32. Second-line, low-dose, weekly paclitaxel in patients with stage IIIB/IV nonsmall cell lung carcinoma who fail first-line chemotherapy with carboplatin plus paclitaxel.
Socinski MA; Schell MJ; Bakri K; Peterman A; Lee JH; Unger P; Yates S; Hudgens S; Kies MS
Cancer; 2002 Sep; 95(6):1265-73. PubMed ID: 12216094
[TBL] [Abstract][Full Text] [Related]
33. Economic analysis of the TAX 317 trial: docetaxel versus best supportive care as second-line therapy of advanced non-small-cell lung cancer.
Leighl NB; Shepherd FA; Kwong R; Burkes RL; Feld R; Goodwin PJ
J Clin Oncol; 2002 Mar; 20(5):1344-52. PubMed ID: 11870178
[TBL] [Abstract][Full Text] [Related]
34. Overview of docetaxel (Taxotere) in the treatment of non-small cell lung cancer.
Fossella FV
Semin Oncol; 1999 Jun; 26(3 Suppl 11):4-8. PubMed ID: 10458203
[TBL] [Abstract][Full Text] [Related]
35. Phase II trial of weekly docetaxel in second-line therapy for nonsmall cell lung carcinoma.
Lilenbaum RC; Schwartz MA; Seigel L; Belette F; Blaustein A; Wittlin FN; Davila E
Cancer; 2001 Oct; 92(8):2158-63. PubMed ID: 11596033
[TBL] [Abstract][Full Text] [Related]
36. Phase II study of docetaxel in the treatment of patients with advanced non-small cell lung cancer in routine daily practice.
Mattson K; Bosquee L; Dabouis G; Le Groumellec A; Pujol JL; Marien S; Stupp R; Douillard JY; Brägas B; Berille J; Olivares R; Le Chevalier T
Lung Cancer; 2000 Sep; 29(3):205-16. PubMed ID: 10996423
[TBL] [Abstract][Full Text] [Related]
37. Docetaxel as neoadjuvant therapy for radically treatable stage III non-small-cell lung cancer: a multinational randomised phase III study.
Mattson KV; Abratt RP; ten Velde G; Krofta K
Ann Oncol; 2003 Jan; 14(1):116-22. PubMed ID: 12488303
[TBL] [Abstract][Full Text] [Related]
38. Quality of life assessment of second-line docetaxel versus best supportive care in patients with non-small-cell lung cancer previously treated with platinum-based chemotherapy: results of a prospective, randomized phase III trial.
Dancey J; Shepherd FA; Gralla RJ; Kim YS
Lung Cancer; 2004 Feb; 43(2):183-94. PubMed ID: 14739039
[TBL] [Abstract][Full Text] [Related]
39. A rapid and systematic review of the effectiveness and cost-effectiveness of the taxanes used in the treatment of advanced breast and ovarian cancer.
Lister-Sharp D; McDonagh MS; Khan KS; Kleijnen J
Health Technol Assess; 2000; 4(17):1-113. PubMed ID: 11074389
[TBL] [Abstract][Full Text] [Related]
40. [Docetaxel (taxotere): current status of clinical development in non-small-cell bronchial carcinoma (NSCLC)].
Manegold C
Med Klin (Munich); 1998 Sep; 93 Suppl 3():16-21. PubMed ID: 9796220
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
